ScreenerHero

CCCC C4 Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · c4therapeutics.com
2.820USD-2.08%Mkt Cap: 346.93M $P/E: —

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap346.93M USD
Enterprise Value157.51M USD
Revenue (TTM)35.04M USD
Gross Profit30.25M USD
Net Income (TTM)-104.99M USD
Revenue/Share0.31 USD
Last Price2.820 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees104
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.89
PEG—
EV/EBITDA-1.58
EV/Revenue4.50
P/S10.11
P/B1.43
EPS (TTM)-0.91
EPS (Forward)-1.00
52W Range
1.69032% of range5.170
52W High5.170 USD
52W Low1.690 USD
Profitability
Gross Margin86.34%
Oper. Margin-397.88%
EBITDA Margin-283.82%
Profit Margin-292.08%
ROE-40.92%
ROA-29.24%
Growth
Revenue Growth2.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-98.69M USD
CapEx (TTM)607.00K USD
FCF Margin-124.62%
FCF Yield-12.59%
Net Debt-196.81M USD
Net Debt/EBITDA1.98
Balance Sheet
Debt/Equity0.23
Current Ratio5.45
Quick Ratio5.29
Book Value/Sh2.01 USD
Cash/Share2.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.33 USD
Upside (mean)+372.8%
Target Range7.000 USD – 30.00 USD
7.000+372.8% to mean30.00
# Analysts6
Ownership
Shares Out.123.03M
Float94.50M
Insiders0.84%
Institutions103.09%
Short Interest
Short Ratio19.8d
Short % Float32.86%
Short % Out.32.67%
Shares Short40.19M
Short (prev mo.)34.05M
Technical
SMA 503.620 (-22.1%)
SMA 2003.118 (-9.6%)
Beta3.08
S&P 52W Chg16.45%
Avg Vol (30d)2.08M
Avg Vol (10d)2.46M
Technical Indicators
RSI (14)32.2
MACD-0.2090
MACD Signal-0.1851
MACD Hist.-0.0239
BB Upper3.659 USD
BB Middle3.210 USD
BB Lower2.762 USD
BB Width27.95%
ATR (14)0.2175 USD
Vol Ratio (20d)1.06x